The Potential Role of Serotonergic Hallucinogens in Depression Treatment

• Main Authors: Dominika Psiuk, Emilia Nowak, Krystian Cholewa, Urszula Łopuszańska, Marzena Samardakiewicz
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Life
• Subjects: psychedelics; depression; serotonergic hallucinogens; psilocybin; MDMA; LSD
• Online Access: https://www.mdpi.com/2075-1729/11/8/765

Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic substances for the treatment of depression. A literature search of the PubMed/MEDLINE database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, MDMA, DMT, or LSD for the treatment of depression symptoms. Some psychedelics, especially psilocybin, demonstrated an ability to reduce depressive symptoms as measured by several psychological scales, which was often sustained for months after the last psychedelic session. Moreover, one study revealed that psilocybin has comparable efficacy to escitalopram in the treatment of depression. None of the studies reported any serious adverse events associated with psychedelic administration. The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.